People With Health Anxiety Die Earlier. A Major Swedish Study Finally Shows Why That Matters

People diagnosed with hypochondriasis, the persistent, disabling preoccupation with having a serious physical illness, do not live as long as their peers, and the gap is larger than most clinicians would expect. A nationwide Swedish matched-cohort study published in JAMA Psychiatry tracked 4,129 individuals with an ICD-10 diagnosis of hypochondriasis against 41,290 matched controls from 1997 to 2020. The findings reveal a stark paradox: people consumed by fear of fatal disease still die earlier, and much of that excess mortality is preventable.

Hypochondriasis Mortality Rate Nearly 70% Higher Than Matched Controls

The core numbers are hard to set aside. Individuals with hypochondriasis had a hazard ratio of 1.69 (95% CI, 1.47 to 1.93) for all-cause mortality compared to matched controls, meaning they were 69% more likely to die during the follow-up period. Crude mortality rates reflect the same pattern: 8.5 deaths per 1,000 person-years in the hypochondriasis group versus 5.5 per 1,000 in controls. On average, people with hypochondriasis died at age 70.0, compared to 75.1 for controls, a gap of more than five years. The elevated risk appeared early in follow-up and was broadly consistent between women and men.

The researchers used data linked from multiple Swedish population-based registers, including the National Patient Register and the Cause of Death Register. Individuals with dysmorphophobia were excluded to reduce misclassification, and the ICD code used carries an 80% true-positive rate and 95% interrater reliability, lending the diagnostic classification credibility.

Suicide Accounts for Most of the Excess Unnatural Deaths

Beyond natural causes, the unnatural cause mortality hazard ratio reached 2.43 (95% CI, 1.61 to 3.68). Suicide drove most of that excess, with a fourfold increased risk (HR, 4.14; 95% CI, 2.44 to 7.03). That figure attenuated after adjusting for lifetime depressive and anxiety disorders, which is unsurprising given how tightly these conditions cluster in this population: 85.7% of people with hypochondriasis carried at least one other lifetime psychiatric diagnosis. A post-hoc analysis limiting comorbidities to those diagnosed before the hypochondriasis diagnosis did preserve statistical significance for suicide risk, suggesting the disorder itself contributes independent risk beyond simply co-occurring depression.

This matters for clinical practice. Chronic anxiety and depression are well-documented contributors to cardiovascular disease and premature death, and the burden they place on individuals and health systems is substantial. In hypochondriasis, those pathways appear to be running in parallel with the disorder's defining features rather than separately from them.

How the Study Isolated Hypochondriasis From General Psychiatric Risk

The Swedish health system offered a methodological advantage unavailable in most countries. Sweden's implementation of ICD-10 includes a separate diagnostic code for hypochondriasis (F45.2), distinct from dysmorphophobia (F45.2A), which allowed researchers to assemble a comparatively clean cohort. Participants were matched by sex, birth year, and county of residence, and analyses used stratified Cox proportional hazards regression adjusting for sociodemographic variables and lifetime psychiatric comorbidities.

Among natural causes of death, circulatory system diseases, respiratory diseases, and deaths from unspecified symptoms or signs were the most common. Notably, risk of death from neoplasms was comparable between the hypochondriasis and control groups. That finding undercuts a straightforward medical-avoidance explanation: if people with hypochondriasis were simply avoiding doctors and dying of undetected cancers, you would expect cancer mortality to be disproportionately elevated. It was not. Instead, the mechanisms driving excess mortality appear to involve chronic physiological stress: dysregulated HPA-axis activity, immune dysfunction, chronic inflammation, and lifestyle factors including alcohol and substance use.

Individuals diagnosed in inpatient settings showed higher risks of both all-cause and natural-cause mortality than those diagnosed in outpatient settings, pointing toward a severity gradient within the disorder.

Gaps in the Evidence and What the Study Could Not Measure

The authors are direct about the study's limits. Hypochondriasis is severely underdiagnosed in Sweden and elsewhere: health professionals often fail to recognize it, and the diagnostic label itself carries stigma that discourages recording. Primary care data, where many people with hypochondriasis first present, were not included. This means the study cohort likely skews toward more severe, recognized cases, and true excess mortality in the broader population of people with health anxiety may look different.

The analysis could not adjust for somatization disorder due to database constraints, and limited statistical power prevented separate examination of several specific causes of death. Sociodemographic covariates were measured at the end of follow-up rather than at baseline, which clouds whether variables like income and education were confounders or mediators of the mortality relationship.

Questions about optimal treatment approaches for this population remain open. Evidence-based psychological therapies exist, including internet-delivered self-help formats that lower access barriers, but uptake is constrained by underdiagnosis and care fragmentation.

Integrated Psychiatric and Somatic Care as the Next Clinical Target

The study's practical implication is direct: hypochondriasis should be recognized and treated as a serious disorder with real physical consequences, not dismissed as medically unexplained anxiety. Integrated care that addresses both the psychological disorder and its downstream somatic risks is the logical response. The authors emphasize improved detection as a prerequisite, since a disorder this consistently underdiagnosed cannot be treated at scale if clinicians are not identifying it.

For the suicide risk specifically, the data reinforce the urgency of connecting people with hypochondriasis to mental health services that can address the comorbid depression driving much of that excess. Research into prolonging the effects of rapid-acting interventions in high-risk populations continues to develop; combining a ketamine infusion with low-dose buprenorphine has shown promise for extending antisuicidal effects by at least a month in people with major depressive disorder and suicidal ideation, a finding with potential relevance to severe hypochondriasis cases involving comorbid depression. Whether that kind of approach translates to this specific population remains to be studied, but systematic reviews continue to probe the conditions under which ketamine reduces suicidal ideation across different presentations.

The broader takeaway from the Swedish data is that fear of illness and actual illness are not opposites. For thousands of people living with hypochondriasis, chronic psychological distress is already translating into years of life lost.

Evidence rating

EMERGING — 67/100

Caveats:

• Observational cohort design — shows association, not causation.
• Funding source not disclosed in the article.
• Hypochondriasis is severely underdiagnosed in Sweden, so the registered cohort likely represents more severe cases, which may overstate population-level risk.
• Primary care data were not included, limiting generalizability.
• Proposed biological mechanisms (HPA axis dysregulation, chronic inflammation) are speculative and not directly measured in this study.

Nationwide matched-cohort study from Sweden (n=4,129 hypochondriasis cases; n=41,290 matched controls) spanning 1997–2020. Reports associations between hypochondriasis diagnosis and elevated all-cause, natural-cause, and suicide mortality using Cox regression; as an observational design it cannot establish causation. No prior large-scale replication of this specific mortality question exists, though proposed mechanisms remain speculative.

References

1. David Mataix-Cols, Kayoko Isomura, Anna Sidorchuk, et al. (2024). All-Cause and Cause-Specific Mortality Among Individuals With Hypochondriasis. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2023.4744
2. Rute Dinis Sousa, Miguel Gouveia, Catarina Nunes-da-Silva, et al. (2021). Treatment-Resistant Depression and Major Depression With Suicide Risk – The Cost of Illness and Burden of Disease. https://doi.org/10.21203/rs.3.rs-757712/v1
3. Drug combo is the first to prolong ketamine's antisuicide effects – Stanford Medicine. med.stanford.edu. https://med.stanford.edu/news/all-news/2026/05/ketamine-suicidal-ideation.html
4. Ya-Ting Wang, Xiao-Le Wang, Lan Lei, et al. (2023). A systematic review and meta-analysis of the efficacy of ketamine and esketamine on suicidal ideation in treatment-resistant depression. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-023-03605-1